More than 1,000 patients with an incurable type of blood cancer are expected to benefit from a “completely new” treatment that will be subsidised by the Federal Government in the new year.

Darzalex, which will be listed on the Pharmaceutical Benefits Scheme (PBS) from January 1, is a medicine used to treat multiple myeloma, a cancer that causes cancerous plasma cells to accumulate in bone marrow and crowd out healthy blood cells.

An estimated 18,000 to 20,000 people are living with multiple myeloma and about 1,000 die with it each year, Myeloma Australia chief executive Steve Roach said.

Miles Prince, the director of molecular oncology and cancer immunology at Epworth Health Care, said treatment options for the cancer had been “quite limited”.

Read More

Most Recent Report On The Global “Cancer Metabolism Based Therapeutics Market”

The Cancer Metabolism Based Therapeutics Market report is an investigative study of the market, along with an analysis of its key segments. The report is constructed through primary and secondary research. The insightful data of the market is generated through interviews and data collection from the industry experts and professionals. The study is an extensive document of the key aspects of the markets, including trends, segmentation, growth prospects, opportunities, challenges, and competitive analysis.

The Cancer Metabolism Based Therapeutics Market study is a well-researched report encompassing a detailed analysis of this industry with respect to certain parameters such as the production capacity as well as the overall market remuneration. The report enumerates details about production and consumption patterns in the business as well, in addition to the current scenario of the Cancer Metabolism Based Therapeutics market and the trends that will prevail in this industry.

According to the study published in the Journal of Cancer Biology and Therapy, 2013, the controversial discovery of the 20^th century by Otto Warburg led to study of metabolic activity in cancerous tissue, which increases the amount of production of lactate from glucose by tenfold under aerobic condition. This has revealed that heterogeneity is developed at cellular level leading to proliferation of cancerous cells due to increased metabolism rate. Cancer metabolism is based on the principle of cancer cells, which alter the metabolism of glucose and glutamine for the synthesis of lipids, nucleotides, fatty acids, and proteins that helps to proliferate cancer cells. It results in inhibition of various metabolic pathways, such as the citric acid cycle, glucose, mitochondrial respiration, and glutamine utilization. Limited options of cancer metabolism targeting therapies are expected provide potential opportunities for development of novel cancer metabolism-based therapeutics in the near future.

Read More

Cancer immunotherapy also called biologic therapy, can predominantly be classed as a form of targeted therapy, It is designed to stimulate the body’s immune system to attack tumors.
The global Cancer Immunotherapies market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Cancer Immunotherapies market based on company, product type, end-user and key regions.

This report studies the global market size of Cancer Immunotherapies in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Cancer Immunotherapies in these regions.

Read More